SCHEMBL6324873

SCHEMBL6324873

CN1C(=O)/C(=N\O)c2c1ccc(Cl)c2Cl

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.36
KMT2A Q03164 2/20 0.36
MAPT P10636 2/20 0.36
CA1 P00915 3/20 0.33
CA2 P00918 3/20 0.33
TTR P02766 2/20 0.33
CA9 Q16790 2/20 0.33
CA12 O43570 1/20 0.33
KDR P35968 1/20 0.33
NOTUM Q6P988 1/20 0.33
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
HTR2B P41595 1/20 0.32
TGM2 P21980 1/20 0.32
HPGD P15428 2/20 0.31
F2 P00734 1/20 0.31
ATM Q13315 1/20 0.31
LRRK2 Q5S007 1/20 0.31
KDM4E B2RXH2 1/20 0.31
CES1 P23141 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6317683 1.00 ALDH1A1 (0.36) ALDH1A1KMT2AMAPTCA1CA2
SCHEMBL6318293 0.81 ALDH1A1 (0.38) ALDH1A1KMT2AMAPTCA1CA2
SCHEMBL6318296 0.81 ALDH1A1 (0.38) ALDH1A1KMT2AMAPTCA1CA2
SCHEMBL6324474 0.78 CES1 (0.41) ALDH1A1CA1CA2TTRNOTUM
SCHEMBL6316917 0.74 ALDH1A1 (0.37) ALDH1A1KMT2AMAPTTTRCA9
SCHEMBL6318515 0.70 CA9 (0.39) ALDH1A1KMT2AMAPTCA1CA2
SCHEMBL6318430 0.70 CA9 (0.39) ALDH1A1KMT2AMAPTCA1CA2
SCHEMBL5190480 0.68 CA2 (0.44) ALDH1A1KMT2AMAPTCA1CA2
SCHEMBL5190489 0.68 CA2 (0.44) ALDH1A1KMT2AMAPTCA1CA2
SCHEMBL5194875 0.66 TTR (0.65) ALDH1A1KMT2AMAPTCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6969729-B2 Use of isatin derivatives as ion channel activating agents NEUROSEARCH A/S (DK) 2005-11-29 US claimed
US-20030114513-A1 Use of isatin derivatives as ion channel activating agents NEUROSEARCH A/S 2003-06-19 US claimed
US-6969729-B2 Use of isatin derivatives as ion channel activating agents NEUROSEARCH A/S (DK) 2005-11-29 US disclosed
US-20030114513-A1 Use of isatin derivatives as ion channel activating agents NEUROSEARCH A/S 2003-06-19 US disclosed
EP-0432648-B1 Isatine derivatives, their preparation and use NEUROSEARCH AS (DK) 1995-08-02 EP disclosed
US-5198461-A Isatine derivatives, their preparation and use NEUROSEARCH A/S (DK) 1993-03-30 US disclosed
EP-0432648-A2 Isatine derivatives, their preparation and use NEUROSEARCH A/S (DK) 1991-06-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114513-A1 Use of isatin derivatives as ion channel activating agents KCNN3, KCNJ2, KCND2 ALDH1A1 3865/4885KMT2A 2004/4885MAPT 1939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.